(ATHA) – Hot Corp. News
-
Athira Pharma Inc. (ATHA) plunges 60% after ACT-AD Phase 2 study of Fosgonimeton in Alzheimer’s fails to hit primary endpoint
-
Athira Pharma (ATHA) CEO Placed on Temporary Leave Pending Board Review of Actions Stemming from Doctoral Research while at Washington State University
Back to ATHA Stock Lookup
